• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES GORE PROPATEN VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES GORE PROPATEN VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT Back to Search Results
Device Problem Complete Blockage (1094)
Patient Problem Occlusion (1984)
Event Date 01/01/2018
Event Type  Injury  
Manufacturer Narrative
Review of the manufacturing records could not be performed as no lot number information was provided.The device was not returned.Consequently, direct product analysis was not possible.Additional information about this event could not be obtained.As a result, no conclusion can be drawn.All information has been placed on file for use in tracking and trending.
 
Event Description
Published article 'comparison of propaten heparin-bonded vascular graft with distal anastomotic patch versus autogenous saphenous vein graft in tibial artery bypass' (jeremy kaisar, m.D.; aaron chen, m.D.; mathew cheung, m.D.; elias kfoury, m.D.; carlos bechara, m.D.And peter lin, m.D.; vascular 2018, vol.26(2) 117¿125; journals.Sagepub.Com/home/vas) was reviewed.The purpose of this study is to analyze experiences with tibial artery revascularization using heparin-bonded eptfe gore® propaten® vascular grafts with distal anastomotic patch and autogenous saphenous vein conduits.A retrospective review of a prospectively collected database was performed for all patients undergoing tibial artery bypass from january 2001 to june 2016 at two university-affiliated academic medical centers.The article reported on page 120 graft occlusion occurred in 17 propaten patients within 30 days of implant.
 
Manufacturer Narrative
Additional manufacturing narrative: c1.Name (#1) - cbas® heparin surface; manufacturer/compounder: w.L.Gore & associates, inc.Lot #unk.Cbas® heparin surface incorporates cbas-heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE PROPATEN VASCULAR GRAFT
Type of Device
PROSTHESIS, VASCULAR GRAFT
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
MDR Report Key10123503
MDR Text Key194149161
Report Number2017233-2020-00403
Device Sequence Number1
Product Code DSY
Combination Product (y/n)N
PMA/PMN Number
K062161
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Type of Report Initial,Followup
Report Date 07/30/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/05/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age73 YR
-
-